Financial Performance - Total revenue for Q1 2020 was CNY 139,506,502.75, an increase of 3.66% compared to CNY 134,580,507.88 in the same period last year[8] - Net profit attributable to shareholders was a loss of CNY 13,453,684.69, representing a decline of 114.17% from a loss of CNY 6,281,688.10 in the previous year[8] - Operating income increased by 3.66% year-on-year, with the blood products segment seeing nearly 50% growth, while the in vitro diagnostics business experienced a 60% decline in revenue[23] - Net profit attributable to the parent company was CNY -13.4537 million, a decline of 114.17% year-on-year, primarily due to the impact of the COVID-19 pandemic[20] - Net loss for Q1 2020 was CNY 10,424,978.03, compared to a net loss of CNY 4,365,383.99 in Q1 2019, representing a 138.5% increase in losses[45] - The company reported a total comprehensive loss of CNY 10,500,197.83 for Q1 2020, compared to a loss of CNY 5,010,249.33 in Q1 2019[45] Cash Flow - Net cash flow from operating activities improved to CNY 21,810,011.14, a significant increase of 146.50% compared to a negative cash flow of CNY 46,907,435.82 in the same period last year[8] - Cash received from operating activities increased by CNY 4.2577 million, a rise of 94.29%, mainly due to an increase in bid deposits received[21] - Cash paid for purchasing goods and services decreased by CNY 37.5708 million, a reduction of 42.88%, due to restrictions on operations caused by the COVID-19 pandemic[22] - Cash inflow from financing activities was CNY 953,251,255.00, a substantial increase from CNY 124,285,772.43 in the previous period[52] - The company reported a net cash increase of CNY 49,118,542.21, contrasting with a decrease of CNY 24,544,644.00 in the previous period[53] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,713,204,052.21, reflecting a 0.69% increase from CNY 2,694,604,343.18 at the end of the previous year[8] - Total liabilities increased to CNY 1,671,558,297.02 from CNY 1,642,458,390.15, representing a rise of approximately 1.1%[36] - The company's equity attributable to shareholders decreased to CNY 1,018,206,404.94 from CNY 1,031,395,597.18, a decline of approximately 1.3%[37] - Current assets totaled CNY 1,006,162,378.99, up from CNY 983,157,351.57, indicating an increase of about 2.5%[34] - The company's total liabilities decreased to CNY 750,079,091.32 from CNY 1,133,987,940.89 year-over-year[44] Expenses - Financial expenses increased by CNY 4.0127 million, a growth of 67.07%, mainly due to increased interest expenses from bank loans and inter-company borrowings[19] - Research and development expenses for Q1 2020 were CNY 10,661,711.55, a decrease of 19.2% from CNY 13,196,333.60 in the same period last year[44] - The company reported a significant increase in income tax expenses by CNY 1.6088 million, a rise of 169.63%, due to the reversal of deferred tax assets[19] Shareholder Information - The company reported a total of 25,120 common shareholders at the end of the reporting period[12] Future Outlook - The company expects a gradual improvement in performance in Q2 2020, although overall losses are anticipated for the first half of the year due to the pandemic's impact[28] - The company is exploring new product development and market expansion opportunities to enhance revenue streams in the upcoming quarters[50] Changes in Financial Reporting - The company has implemented new revenue and leasing standards starting in 2020, with no retrospective adjustments made to prior period data[63]

Financial Performance - Operating revenue for the reporting period was CNY 167,780,231.32, an increase of 4.70% year-on-year[8] - Net profit attributable to shareholders decreased by 47.21% to CNY 3,267,994.90[8] - Basic earnings per share were CNY 0.0040, down 47.37% compared to the same period last year[8] - Investment income for the period was CNY 156.52 million, reflecting a decrease from the previous year's CNY 352.18 million due to the recognition of equity compensation[20] - The total profit for the current period was ¥5,745,043.85, down from ¥11,139,909.37 in the previous period[42] - The net profit for Q3 2019 was CNY 8,627,171.12, a decrease of 69.9% from CNY 28,721,165.26 in the same period last year[50] - Comprehensive income for the current period totaled ¥3,981,748.75, down from ¥10,663,042.87 in the previous period[42] - The company's operating revenue for Q3 2019 was CNY 162,371,553.11, an increase of 8.3% compared to CNY 149,979,806.56 in Q3 2018[53] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,648,914,362.58, a decrease of 2.34% compared to the end of the previous year[8] - The company's total liabilities reached CNY 1,603,565,767.16, up from CNY 1,468,410,939.03, indicating a rise of 9.2%[33] - Current liabilities totaled CNY 1,264,644,733.62, compared to CNY 1,252,671,478.33 in the previous period, reflecting an increase of approximately 1.5%[33] - Long-term borrowings increased significantly to CNY 217,544,859.15 from CNY 106,100,000.00, representing a growth of 104.1%[33] - Cash and cash equivalents decreased by 75.10% compared to the beginning of the year, primarily due to a reduction in available working capital[19] - Cash and cash equivalents at the end of the period decreased to 25,521,698.75 CNY from 58,968,392.31 CNY, indicating a decline in liquidity[58] Shareholder Information - The company reported a total of 18,987 common shareholders at the end of the reporting period[12] - The top shareholder, Du Jiangtao, holds 39.03% of the shares, amounting to 318,811,388 shares[12] - The total equity attributable to shareholders decreased to CNY 1,019,953,617.76 from CNY 1,173,270,705.96, a decline of 13.1%[34] Cash Flow - The net cash flow from operating activities was CNY -43,150,496.29, a decrease of 30.56% year-on-year[8] - Cash flow from operating activities increased to CNY 510,538,187.72, compared to CNY 423,216,336.39 in Q3 2018[56] - Total cash inflow from financing activities increased to 657,376,480.66 CNY, compared to 366,786,408.00 CNY in the prior period, reflecting a significant rise in borrowing[58] - The total cash outflow for financing activities was 584,085,726.01 CNY, significantly higher than 267,100,332.36 CNY in the previous period, reflecting increased financial obligations[58] Expenses and Costs - Total operating costs increased to ¥160,986,669.70, up 7.9% from ¥149,145,891.68 in the previous period, with operating costs specifically rising to ¥86,500,089.70 from ¥77,413,394.21[41] - Financial expenses increased by CNY 4.30 million, a rise of 31.13%, mainly due to increased interest expenses from higher borrowings[20] - The company paid 160,698,149.87 CNY to employees, an increase from 131,378,035.09 CNY, reflecting higher labor costs[57] Research and Development - The company reported a significant increase in research and development expenses, totaling ¥13,008,593.64, compared to ¥12,952,626.87 in the previous period[41] - Research and development expenses rose to CNY 39,246,495.87, up 11.8% from CNY 35,089,152.21 in Q3 2018[53] Future Outlook - The company expects a significant decline in cumulative net profit compared to the same period last year, primarily due to reduced impacts from equity compensation and goodwill impairment[23] - The company plans to continue focusing on R&D and market expansion to improve future performance[50]

北京博晖创新生物技术股份有限公司 2019 年半年度报告全文 北京博晖创新生物技术股份有限公司 2019 年半年度报告 定 2019-04 2019 年 08 月 1 北京博晖创新生物技术股份有限公司 2019 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人卢信群、主管会计工作负责人牛树荟及会计机构负责人(会计主 管人员)李娟声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | | | | 2019 | 年半年度报告 1 | | --- | --- | | 第一节 | 重要提示、释义 1 | | 第二节 | 公司简介和主要财务指标 4 | | 第三节 | 公司业务概要 6 | | 第四节 | 经营情况讨论与分析 10 | | 第五节 | 重要事项 14 | | 第六节 | 股份变动及股东情况 15 | | 第七节 | 优先股相关情况 16 ...

Financial Performance - Total revenue for Q1 2019 was ¥134,580,507.88, an increase of 4.62% compared to ¥128,637,899.74 in the same period last year[8] - Net profit attributable to shareholders was -¥6,281,688.10, a decrease of 183.42% from ¥7,530,601.21 in the previous year[8] - Basic earnings per share decreased by 183.70% to -¥0.0077 from ¥0.0092 in the same period last year[8] - Operating income increased by 4.62% year-on-year, with the parent company benefiting from an 18% increase in microfluidic product revenue[23] - The company reported a net operating loss of CNY -3,311,283.65 for Q1 2019, compared to a profit of CNY 10,316,428.21 in the previous year[41] - The net profit for Q1 2019 was a loss of CNY 4,365,383.99, compared to a profit of CNY 8,326,652.67 in Q1 2018, indicating a significant decline[43] - The total comprehensive income for Q1 2019 was a loss of CNY 5,010,249.33, compared to a gain of CNY 7,149,405.62 in Q1 2018[43] Cash Flow - Net cash flow from operating activities was -¥46,907,435.82, a decline of 27.37% compared to -¥36,828,618.07 in the previous year[8] - Cash flow from operating activities related to other payments increased by 59.56% year-on-year, attributed to higher sales and R&D expenses[21] - The operating cash flow for Q1 2019 was a net outflow of CNY 46,907,435.82, worsening from a net outflow of CNY 36,828,618.07 in the same period last year[50] - The net cash flow from operating activities was -20,815,200.73 RMB, compared to -6,609,913.82 RMB in the previous period, indicating a significant decline in operational cash flow[53] - The company received cash inflows from financing activities totaling 124,285,772.43 RMB, while cash outflows were 71,305,715.68 RMB, resulting in a net cash flow of 52,980,056.75 RMB from financing activities[51] - Cash inflows from investment activities were 23,000,000.00 RMB, while cash outflows were 37,493,636.90 RMB, leading to a net cash flow of -14,493,636.90 RMB from investment activities[54] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,747,072,246.19, an increase of 1.28% from ¥2,712,341,755.90 at the end of the previous year[8] - Total liabilities increased to CNY 1,031,430,007.15 in Q1 2019 from CNY 980,172,142.99 in the previous year, marking an increase of approximately 5.2%[40] - The company's total equity as of March 31, 2019, was CNY 1,625,734,396.21, slightly up from CNY 1,625,617,866.41 at the end of 2018[40] - The company’s total assets amounted to CNY 2.747 billion as of March 31, 2019, compared to CNY 2.712 billion at the end of 2018[34] - Total current assets amounted to CNY 675,172,919.44, with cash and cash equivalents at CNY 28,721,506.86[61] - Total non-current assets reached CNY 1,930,617,089.96, including long-term equity investments of CNY 1,511,338,284.19[61] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 20,892[12] - The company has not conducted an audit for the first quarter report, which may affect the reliability of the financial data presented[63] Operational Costs and Expenses - Total operating costs for Q1 2019 were CNY 138,047,954.69, up from CNY 118,503,228.43, indicating an increase of about 16.5% year-over-year[41] - Research and development expenses for Q1 2019 were CNY 13,196,333.60, compared to CNY 10,453,698.14 in the same period last year, indicating an increase of about 26.4%[41] - The company reported a decrease in income tax expenses by CNY 1.2772 million, a reduction of 57.38%, due to a decrease in total profit[20] - Financial expenses increased by CNY 2.2936 million, a growth of 62.17%, mainly due to increased interest expenses from bank loans and inter-company borrowings[20] - The company incurred financial expenses of CNY 3,876,400.23 in Q1 2019, compared to CNY 2,323,916.14 in Q1 2018, indicating increased borrowing costs[46] Other Financial Metrics - Other comprehensive income decreased by 782.47% year-on-year, primarily due to foreign currency translation adjustments[19] - Cash and cash equivalents increased to CNY 47,948,599.20 as of March 31, 2019, compared to CNY 28,721,506.86 at the end of 2018, reflecting a growth of approximately 67.2%[38] - The company reported sales revenue from goods and services of 42,863,089.85 RMB, an increase from 33,397,782.99 RMB in the previous period, representing a growth of approximately 28.5%[53] - The company reported other income of CNY 145,248.17 in Q1 2019, slightly down from CNY 152,707.91 in Q1 2018[46]

Financial Performance - The company's operating revenue for 2018 was CNY 622,093,848.04, representing a 40.19% increase compared to CNY 443,754,419.40 in 2017[15]. - The net profit attributable to shareholders for 2018 was CNY 69,438,286.13, a significant increase of 78.73% from CNY 38,850,990.10 in 2017[15]. - The basic earnings per share for 2018 was CNY 0.0848, up 78.15% from CNY 0.0476 in 2017[15]. - The company reported a net profit of CNY 137,976,966.72 for the year 2018, a decrease from CNY 319,713,808.01 in 2017, reflecting a decline of approximately 57%[21]. - The company achieved blood product revenue of CNY 326.84 million, a year-on-year increase of 76.56%[60]. - The total revenue for the reporting period was CNY 622.09 million, representing a 40.19% increase compared to CNY 443.75 million in the previous year[67]. Cash Flow and Investments - The net cash flow from operating activities for 2018 was -CNY 84,149,883.86, showing an improvement of 11.60% compared to -CNY 95,194,050.69 in 2017[15]. - Total operating cash inflow increased by 30.87% year-on-year to ¥612,020,524.38, primarily due to increased sales revenue[89]. - Total cash inflow from investing activities decreased by 53.16% year-on-year to ¥38,636,110.73, mainly due to increased cash flow from short-term idle fund management[90]. - Total cash outflow from investing activities decreased by 55.31% year-on-year to ¥86,292,266.70, with no significant investment activities in 2018[90]. - The significant difference between net cash flow from operating activities and net profit was mainly due to asset impairment provisions of ¥73,729,200 and fair value changes of -¥195,666,000[93]. Market and Industry Insights - The company operates in the in-vitro diagnostics (IVD) sector, which accounted for 13% of the global medical device market, with sales reaching USD 52.6 billion in 2017[30]. - The global IVD market size was approximately $60 billion in 2016, with an expected CAGR of about 5%, reaching $78.7 billion by 2021[1]. - China's IVD market size reached approximately 60 billion yuan in 2017, projected to grow to 72.3 billion yuan by 2019, with a CAGR of about 15% over the past five years[1]. - The concentration of the IVD industry in China is low, with over 600 companies, and the top 20 companies holding only about 30% market share, indicating opportunities for growth[5]. Research and Development - The company has developed a microfluidic chip control technology, which is a domestic innovation and internationally leading, with over 20 patents related to this technology[27]. - The company is actively developing new products, with several products approved for market, including rabies immunoglobulin and tetanus immunoglobulin[62]. - The number of R&D personnel increased to 104 in 2018, up from 101 in 2017 and 89 in 2016[83]. - The R&D investment for the year was ¥75,074,298.65, up from ¥58,590,685.81 in the previous year, indicating a growth of approximately 28.3%[84]. Shareholder and Dividend Information - The company plans to distribute cash dividends to shareholders at a rate of CNY 0 per 10 shares, with no bonus shares issued[5]. - The total cash dividend amount for 2018 was ¥0.00, with no shares distributed or increased[130]. - In 2018, the company achieved a net profit of ¥77,508,382.28, with a distributable profit of ¥352,982,877.38, but opted for no cash dividends, resulting in a 0.00% payout ratio[133]. - The company has maintained compliance with relevant laws and regulations regarding profit distribution and shareholder rights[137]. Operational Strategies - The company is focusing on expanding its blood products business and plans to open new plasma collection stations to enhance production capacity[133]. - The blood products business strategy aims to increase operational efficiency and seek reasonable acquisition opportunities to become a competitive player in the industry within 3-5 years[114]. - The company plans to enhance its marketing efforts by integrating sales from different regions and actively participating in drug bidding processes to increase market share[114]. - The company emphasizes the importance of quality control in its operations, establishing a comprehensive quality management system to mitigate risks associated with product safety[117]. Compliance and Commitments - The company has adhered to all commitments made by shareholders and related parties during the reporting period[140]. - No violations of commitments were reported by the company's actual controllers, shareholders, or related parties during the reporting period[140]. - The profit compensation agreement includes a formula for calculating the number of shares to be repurchased based on the difference between committed and actual profits[143].

所有董事均已出席了审议本次季报的董事会会议。 北京博晖创新生物技术股份有限公司 2018 年第三季度报告全文 北京博晖创新生物技术股份有限公司 2018 年第三季度报告 定 2018-06 2018 年 10 月 1 北京博晖创新生物技术股份有限公司 2018 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 2,531,023,016.65 | 2,737,468,431.65 | | -7.54% | | 归属于上市公司股东的净资产 | 1,113,852,920.84 | 1,474,242,334.41 | | -24.45% | | （元） | | | | | | | 本报告期 | 本报告期比上年同期 增减 | 年初至报告期末 | 年初至报告期末比上 年同期增减 | | 营业收入（元） | ...

北京博晖创新生物技术股份有限公司 2018 年半年度报告全文 北京博晖创新生物技术股份有限公司 2018 年半年度报告 定 2018-04 2018 年 08 月 1 北京博晖创新生物技术股份有限公司 2018 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人卢信群、主管会计工作负责人牛树荟及会计机构负责人(会计主 管人员)李娟声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 2018 | 年半年度报告 2 | | --- | --- | | 第一节 | 重要提示、释义 5 | | 第二节 | 公司简介和主要财务指标 5 | | 第三节 | 公司业务概要 8 | | 第四节 | 经营情况讨论与分析 17 | | 第五节 | 重要事项 28 | | 第六节 | 股份变动及股东情况 35 | | 第七节 | 优先股相关情况 39 | | 第 ...

Financial Performance - Total revenue for Q1 2018 reached ¥128,637,899.74, representing a 54.02% increase compared to ¥83,520,656.10 in the same period last year[7] - Net profit attributable to shareholders was ¥7,530,601.21, a significant increase of 439.86% from ¥1,394,918.33 year-over-year[7] - The net profit after deducting non-recurring gains and losses was ¥7,251,785.49, up 550.05% from ¥1,115,578.70 in the previous year[7] - Basic and diluted earnings per share were both ¥0.0092, reflecting a 441.18% increase compared to ¥0.0017 in the same period last year[7] - The company's operating revenue for the reporting period was RMB 128.64 million, representing a year-on-year increase of 54.02%[24] - Net profit for Q1 2018 was ¥8,326,652.67, compared to ¥1,836,724.71 in Q1 2017, marking a growth of 353%[45] - The total profit for Q1 2018 was CNY 9,299,498.35, an increase from CNY 8,569,013.21 in the previous year, representing a growth of approximately 8.5%[49] - The net profit for Q1 2018 reached CNY 8,137,061.06, compared to CNY 7,497,886.56 in Q1 2017, indicating a year-over-year increase of about 8.6%[49] - Basic and diluted earnings per share for Q1 2018 were both CNY 0.0100, up from CNY 0.0092 in the same period last year, reflecting an increase of approximately 8.7%[49] Assets and Liabilities - Total assets decreased by 11.77% to ¥2,415,168,439.23 from ¥2,737,468,431.65 at the end of the previous year[7] - Net assets attributable to shareholders fell by 25.59% to ¥1,096,933,736.16 from ¥1,474,242,334.41 at the end of the previous year[7] - The company's total assets increased to ¥2,337,954,561.93 from ¥2,176,134,523.73, representing an increase of 7.4%[42] - Total liabilities rose to ¥828,616,196.76, up from ¥675,232,969.62, indicating a growth of 22.7%[42] - Total current liabilities increased from ¥966,929,640.32 to ¥1,096,195,557.38, reflecting a rise of about 13.4%[38] - The total equity attributable to shareholders decreased from ¥1,474,242,334.41 to ¥1,096,933,736.16, a decline of about 25.6%[39] Cash Flow - The company reported a net cash flow from operating activities of -¥36,828,618.07, a slight decline of 4.52% compared to -¥35,235,722.45 in the previous year[7] - Cash inflow from operating activities totaled CNY 121,804,225.06, compared to CNY 103,511,956.17 in the previous year, marking an increase of about 17.7%[51] - Cash outflow from operating activities was CNY 158,632,843.13, up from CNY 138,747,678.62, resulting in a net cash flow from operating activities of CNY -36,828,618.07, slightly worse than CNY -35,235,722.45 in the previous year[52] - Cash inflow from financing activities was CNY 154,586,408.00, down from CNY 201,540,000.00, indicating a decrease of approximately 23.3%[53] - The net cash flow from financing activities was CNY 35,145,857.50, compared to CNY 84,703,847.26 in the previous year, showing a decline of about 58.5%[53] - The ending cash and cash equivalents balance was CNY 56,392,293.50, down from CNY 67,278,025.64 at the beginning of the period, reflecting a decrease of approximately 16.5%[53] Expenses and Investments - The company's financial expenses increased by 80.89% year-on-year, primarily due to an increase in bank borrowings[24] - The company's sales expenses increased by 42.27% year-on-year, reflecting ongoing investments in new product and blood product market expansion[24] - The company's tax expenses increased by 624.93% year-on-year, primarily due to the utilization of previously deductible losses against current profits[25] - Operating costs for the same period were ¥118,503,228.43, up from ¥81,878,930.00, reflecting a rise of approximately 44.7%[44] - The company reported a cash outflow from investment activities of CNY 14,118,032.00, compared to CNY 55,407,312.73 in the previous year, indicating a significant reduction in investment spending[52] Strategic Focus - The company is focusing on enhancing its quality management system to mitigate risks associated with product safety in the biopharmaceutical sector[10] - The company plans to increase investment in product research and development to support the establishment of new plasma collection stations amid regulatory uncertainties[12] - The company aims to strengthen project management and introduce advanced tools to improve the success rate of new product development in the medical device sector[15] Shareholder Information - The company received compensation for 29.72% equity in Hebei Daan, resulting in an increase in its shareholding and a corresponding investment income of RMB 352.20 million[22] - The company's capital reserve decreased by 99.91% compared to the beginning of the year, due to adjustments related to the acquisition of Hebei Daan shares[23] - The company's cash and cash equivalents were impacted by a foreign exchange loss of RMB 380,300, a decrease of 179.52% year-on-year[26] - Accounts receivable increased from ¥86,836,674.49 to ¥95,222,585.48, representing an increase of about 10.5%[36] - Inventory rose from ¥560,156,664.36 to ¥585,091,810.34, indicating an increase of approximately 4.4%[36] - The company's short-term borrowings decreased from ¥201,680,000.00 to ¥151,726,408.00, a decrease of approximately 24.7%[38] - Other payables increased from ¥560,320,599.28 to ¥643,106,233.23, representing an increase of about 14.7%[38] - The company's non-current liabilities remained relatively stable, with a slight decrease from ¥156,844,772.01 to ¥156,112,106.91[38] - The company's retained earnings decreased from ¥299,122,965.40 to ¥295,032,404.99, a decline of about 1.3%[39] Audit Information - The company did not conduct an audit for the Q1 2018 report[57]

北京博晖创新光电技术股份有限公司 2017 年年度报告全文 北京博晖创新光电技术股份有限公司 2017 年年度报告 定 2018-01 2018 年 04 月 1 北京博晖创新光电技术股份有限公司 2017 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人卢信群、主管会计工作负责人牛树荟及会计机构负责人(会计主 管人员)李娟声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本年度报告内容中涉及的未来计划等前瞻性陈述因存在不确定性，不构成 公司对投资者的实质承诺，请投资者注意投资风险。 公司不存在因经营状况、 财务状况和持续盈利能力方面有严重不利影响的风险因素。有关公司可能面对 的风险及公司应对措施等详见本报告第四节"经营情况讨论与分析"中相关内 容。 公司经本次董事会审议通过的利润分配预案为：以 821,410,144 为基数，向 全体股东每 10 股派发现金红利 0.05 元（含税），送红股 0 股（含税） ...

北京博晖创新光电技术股份有限公司 2017 年年度报告全文 北京博晖创新光电技术股份有限公司 2017 年年度报告 定 2018-01 2018 年 04 月 1 北京博晖创新光电技术股份有限公司 2017 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人卢信群、主管会计工作负责人牛树荟及会计机构负责人(会计主 管人员)李娟声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本年度报告内容中涉及的未来计划等前瞻性陈述因存在不确定性，不构成 公司对投资者的实质承诺，请投资者注意投资风险。 公司不存在因经营状况、 财务状况和持续盈利能力方面有严重不利影响的风险因素。有关公司可能面对 的风险及公司应对措施等详见本报告第四节"经营情况讨论与分析"中相关内 容。 公司经本次董事会审议通过的利润分配预案为：以 821,410,144 为基数，向 全体股东每 10 股派发现金红利 0.05 元（含税），送红股 0 股（含税） ...